Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2023 09:15 ET | Source: Disc Medicine Inc

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

WATERTOWN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
October 03, 2023 08:30 ET | Source: Disc Medicine Inc

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
September 20, 2023 16:30 ET | Source: Disc Medicine Inc

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
August 30, 2023 16:15 ET | Source: Disc Medicine Inc

Disc Medicine to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
August 11, 2023 08:00 ET | Source: Disc Medicine Inc

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data from all patients in BEACON to be presented year-end...
July 27, 2023 09:00 ET | Source: Disc Medicine Inc

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
June 22, 2023 16:15 ET | Source: Disc Medicine Inc

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
June 13, 2023 22:39 ET | Source: Disc Medicine Inc

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
June 12, 2023 16:00 ET | Source: Disc Medicine Inc

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

WATERTOWN, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
June 09, 2023 07:00 ET | Source: Disc Medicine Inc

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertin Patients reported significant...